Interpreting Randomized Controlled Trials
Cancers · 22.09.2023 · 15 (19) · 4674
DOI: 10.3390/cancers15194674 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.09.2023. Verfasst von Pavlos Msaouel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, United States Department of Defense, Kidney Cancer Association.
Abstract (Originalsprache)
This article describes rationales and limitations for making inferences based on data from randomized controlled trials (RCTs). We argue that obtaining a representative random sample from a patient population is impossible for a clinical trial because patients are accrued sequentially over time and thus comprise a convenience sample, subject only to protocol entry criteria. Consequently, the trial’s sample is unlikely to represent a definable patient population. We use causal diagrams to illustrate the difference between random allocation of interventions within a clinical trial sample and true simple or stratified random sampling, as executed in surveys. We argue that group-specific statistics, such as a median survival time estimate for a treatment arm in an RCT, have limited meaning as estimates of larger patient population parameters. In contrast, random allocation between interventions facilitates comparative causal inferences about between-treatment effects, such as hazard ratios or differences between probabilities of response. Comparative inferences also require the assumption of transportability from a clinical trial’s convenience sample to a targeted patient population. We focus on the consequences and limitations of randomization procedures in order to clarify the distinctions between pairs of complementary concepts of fundamental importance to data science and RCT interpretation. These include internal and external validity, generalizability and transportability, uncertainty and variability, representativeness and inclusiveness, blocking and stratification, relevance and robustness, forward and reverse causal inference, intention to treat and per protocol analyses, and potential outcomes and counterfactuals.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Statistics, University of California Santa Cruz, Santa Cruz, CA 95064, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Pavlos Msaouel, Juhee Lee
Förderung
- NCI NIH HHS
- United States Department of Defense
- Kidney Cancer Association
- Gateway for Cancer Research
- V Foundation
- NIH/NCI R01
- Cancer Center
Zitieren
APA
Msaouel, P., Lee, J., & Thall, P. F. (2023). Interpreting Randomized Controlled Trials. Cancers, 15(19), 4674. https://doi.org/10.3390/cancers15194674
Vancouver
Msaouel P, Lee J, Thall PF. Interpreting Randomized Controlled Trials. Cancers. 2023;15(19):4674. doi:10.3390/cancers15194674
BibTeX
@article{Msaouel2023,
author = {Msaouel, Pavlos and Lee, Juhee and Thall, Peter F},
title = {Interpreting Randomized Controlled Trials},
journal = {Cancers},
year = {2023},
volume = {15},
number = {19},
pages = {4674},
doi = {10.3390/cancers15194674}
}
EUVIMED